Last reviewed · How we verify
Bemotrizinol (6%)
Bemotrizinol (6%) is a UV filter / Sunscreen agent Small molecule drug developed by dsm-firmenich Switzerland AG. It is currently in Phase 3 development for UV protection and photoprotection in topical sunscreen formulations. Also known as: PARSOL SHIELD, BEMT, bis-ethylhexyloxyphenol methoxyphenyl triazine.
Bemotrizinol is a UV filter that absorbs ultraviolet radiation to protect skin from sun damage.
Bemotrizinol, a sunscreening agent, has been studied in clinical trials for its potential to prevent photoallergic response, absorption, phototoxic response, and sunburn. The trials involved testing 6% Bemotrizinol in sunscreen formulations and petrolatum to evaluate its safety and efficacy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Bemotrizinol (6%) |
|---|---|
| Also known as | PARSOL SHIELD, BEMT, bis-ethylhexyloxyphenol methoxyphenyl triazine |
| Sponsor | dsm-firmenich Switzerland AG |
| Drug class | UV filter / Sunscreen agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Bemotrizinol is a broad-spectrum organic UV absorber that protects against both UVA and UVB radiation by absorbing photons and dissipating the energy as heat. It is formulated as a topical sunscreen agent and is used in dermatological and cosmetic products to prevent photoaging and reduce skin cancer risk.
Approved indications
- UV protection and photoprotection in topical sunscreen formulations
Common side effects
- Skin irritation
- Contact dermatitis
- Photosensitivity reactions
Key clinical trials
- Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial (PHASE3)
- Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol (PHASE2)
- Phototoxicity Potential of 6% Bemotrizinol (PHASE2)
- Photoallergic Potential of 6% Bemotrizinol (PHASE2)
- Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bemotrizinol (6%) CI brief — competitive landscape report
- Bemotrizinol (6%) updates RSS · CI watch RSS
- dsm-firmenich Switzerland AG portfolio CI
Frequently asked questions about Bemotrizinol (6%)
What is Bemotrizinol (6%)?
How does Bemotrizinol (6%) work?
What is Bemotrizinol (6%) used for?
Who makes Bemotrizinol (6%)?
Is Bemotrizinol (6%) also known as anything else?
What drug class is Bemotrizinol (6%) in?
What development phase is Bemotrizinol (6%) in?
What are the side effects of Bemotrizinol (6%)?
Related
- Drug class: All UV filter / Sunscreen agent drugs
- Manufacturer: dsm-firmenich Switzerland AG — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for UV protection and photoprotection in topical sunscreen formulations
- Also known as: PARSOL SHIELD, BEMT, bis-ethylhexyloxyphenol methoxyphenyl triazine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing